EVIDENCE BASED RED CELL TRANSFUSION. Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System

Similar documents
Blood transfusions in sepsis, the elderly and patients with TBI

Transfusion Pitfalls. Objectives. Packed Red Blood Cells. TRICC trial (subgroups): Is transfusion always good? Components

Blood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18

Dr Marina Karakantza Consultant Haematologist, NHSBT

Patient Blood Management: Enough is Enough

Transfusion triggers in acute coronary syndromes: The MINT trial

Transfusion Limbo How Low Will You Go? Safely. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine

Goal Directed Therapy : Liberal vs Restrictive Transfusion.. Syafri Kamsul Arif

Advances in Transfusion and Blood Conservation

Risk of ID transmission. Patient Blood Management - Blood Safety and Component Utilization. Transfusion and Cancer 4/9/2014

Heme (Bleeding and Coagulopathies) in the ICU

Transfusion Medicine Potpourri. BUMC - Phoenix Internal Medicine Residents September 29, 2015

Transfusion & Mortality. Philippe Van der Linden MD, PhD

ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE

Blood transfusions in ICU: double-edged sword. Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal

Blood Transfusion Project. Reducing Transfusion in the MARCQI Population

Objectives. Epidemiology of Sepsis. Review Guidelines for Resuscitation. Tx: EGDT, timing/choice of abx, activated

Mary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital

2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?

Transfusion for the sickest ICU patients: Are there unanswered questions?

Clinical Impact of Red-Cell Storage Lesion A Survey and Possible Consequences

Red blood cell transfusions Risks, benefits, and surprises

Why Old Blood is Bad. tales from the electronic perfusion record. Molly Marko, BS, BSE, CCP Geisinger Health System Danville, Pennsylvania

Evidence-Based. Management of Severe Sepsis. What is the BP Target?

Blood Management: Improve Transfusion, Decrease Costs!

No conflicts of interest to disclose

Transfusions in Acute Care Too Little?

Year in Review: Critical Care Medicine

Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*

Transfusion Practices and Creation of a Registry for Patients with Sickle Cell Disease within the Atlanta Sickle Cell Consortium

TACO CASE STUDIES RTC JUNE Kerry Dowling Blood Transfusion Laboratory Manager Jonathan Ricks Blood Transfusion Nurse Practitioner

Controversies in Transfusion Medicine

Boot Camp Transfusion Reactions

Chest diseases Hospital Laboratory Hematology Practice guidelines

Science Evidence Cost

Patient Blood Management. Marisa B. Marques, MD UAB Department of Pathology November 17, 2016

Transfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention. Khalid Abdulla Sharif, MD, MRCP (UK)*

Transfusion Requirements and Management in Trauma RACHEL JACK

Dilemmas in Septic Shock

2 Liters. Goal: Basic Algorithm Volume Resuscitation in Trauma. Initial Fluids. Blood. Where do Blood Products Come From?

4/5/2018. Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY. I have no financial disclosures

Morris A. Blajchman, MD, FRCP(C) Emeritus Professor, McMaster University Hamilton, Ontario, CANADA

Early Goal-Directed Therapy

EDUCATIONAL COMMENTARY TRANSFUSION-RELATED ACUTE LUNG INJURY

Transfusion Reactions. Directed by M-azad March 2012

What is the Role of Albumin in Sepsis? An Evidenced Based Affair. Justin Belsky MD PGY3 2/6/14

Red Cell Transfusion triggers: A moving target When, who, and how much?

Do PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis. Deborah Cook

Components of Blood. N26 Blood Administration 4/24/2012. Cabrillo College ADN/C. Madsen RN, MSN 1. Formed elements Cells. Plasma. What can we give?

JOURNAL CLUB INDICATIONS FOR AND ADVERSE EFFECTS OF RED CELL TRANSFUSION. Maggie Woods PGY-3

Red blood cell transfusions in the PICU: What & When

Effective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)

How we View & Approach TACO

Fluids in Sepsis: How much and what type? John Fowler, MD, FACEP Kent Hospital, İzmir Eisenhower Medical Center, USA American Hospital Dubai, UAE

Nothing to disclose 9/25/2017

Blood and blood component therapy in the critically ill patient

9/25/2017. Nothing to disclose

Alternatives to RBC Transfusion: Erythropoietin and beyond

OHSU. Update in Sepsis

Medical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011

TACO Est ce que cette complication transfusionnelle peut être prédite et prévenue?

Updates in Sepsis 2017

Blood is serious business

PHYSIOLOGY AND MANAGEMENT OF THE SEPTIC PATIENT

TRANSFUSIONS WHY DO WE EVEN CARE?????

Proceedings of the World Small Animal Veterinary Association Sydney, Australia 2007

Blood Transfusion. Dr William Dooley

Albumina nel paziente critico. Savona 18 aprile 2007

Staging Sepsis for the Emergency Department: Physician

Approach to a patient with suspected blood transfusion reaction. Raju Vaddepally, MD

Three decades of transfusion Toronto, Critical Care Canada Forum, October 30, 2014.

Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)

CrackCast Episode 7 Blood and Blood Components

Topics of this lecture : RBC. Structural characteristics Hemoglobin Erythropoiesis Erythrocytes destruction

Implementation and execution of civilian RDCR programs Minnesota RDCR

Blood Management 2016

Transfusion-related Acute Lung Injury (TRALI) University of California, San Francisco January 8, 2011

Dr Tushar Mahambrey. Consu ltant Critical Care Med icine & Anaesthetics St Helens and Knowsley N H S teaching hospitals Liverpool

Where Blood Matters AIMS. National Scientific Meeting. Darwin Convention Centre September Morteza Mohajeri, MD, FRACS ( Cardiothoracic )

Anaemia in the ICU: Is there an alternative to using blood transfusion?

Cardiogenic Shock. Carlos Cafri,, MD

A Comparative Study Of Autologous Versus Homologous Blood Transfusion During General Surgery

2012, Görlinger Klaus

WHAT S NEW-ISH IN ARDS MANAGEMENT AFTER TRAUMA?

REPORT OF TRANSFUSION ADVERSE REACTION TO BLOOD CENTERS

Crossmatching and Issuing Blood Components; Indications and Effects.

Purist? or Pragmatist? Assessment & Management of ICU Volume Status

MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE

Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill

ORBcoN Spring Symposium April 2015

Written 01/09/17 Rewritten 3/29/17 for Interior Regional EMS Symposium

the bleeding won t stop? Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital

Update in Critical Care Medicine

Are Patients Hypoperfused in the ED? Rapid Perfusion Assessment in the Emergency Department

Olive J Sturtevant, MHP, MT(ASCP)SBB/SLS, CQA Director, Cellular Therapy Quality Assurance Dana Farber Cancer Institute

Inflammatory Statements

Fluid Management in Critically Ill AKI Patients

Austrian Society for Blood Transfusion and Regenerative Medicine. Klagenfurt - May 2015

Sepsis Management Update 2014

Dependance on chronic transfusion

Transcription:

EVIDENCE BASED RED CELL TRANSFUSION Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System

HISTORY Blood transfusion works (ie: red cell transfusion saves lives). based on logic and anecdotal evidence. Blood transfusion works, but is risky: hemolytic transfusion reactions, including death. transmission of diseases: HIV, Hep C etc. other adverse effects of transfusion.

RISKS OF RED CELL TRANSFUSION EARLY COMPLICATIONS (occur during or within hours of transfusion; overall risk <1/1000 units) * 1. Hemolytic Tx reaction * 2. TRALI (Tx related acute lung injury) * 3. Circulatory overload * 4. Anaphylactic reaction 5. Allergic reaction 6. Febrile non-hemolytic reaction * may be fatal

RISKS OF RED CELL TRANSFUSION LATE COMPLICATIONS (occur days to months after transfusion; overall risk >1/100 units) * 1. Delayed hemolytic Tx reaction * 2. Iron overload * 3. IMMUNE SUPPRESSION - increased infections - increased cancer recurrence * 4. TRANSMITTED INFECTIONS - HIV - HCV - HBV * may be fatal

CURRENT VIEW (evidence based) Red cell transfusion offers no benefit to most patients, and often causes serious harm.

EVIDENCE Herbert PC et al: N Engl J Med 1999 Apr1;340(13):1056 - Multicenter prospective randomized controlled study - 838 critically ill adult patients admitted to ICU - Euvolemic after initial treatment - Hemoglobin < 9 g/dl - Randomized into 2 groups: - Restrictive Transfusion group (418 patients) - Liberal Transfusion group (420 patients)

TRICC TRIAL RESTRICTIVE TX GROUP LIBERAL TRANSFUSION GROUP Transfused if Hb < 7 g/dl Transfused if Hb < 10 g /dl Hb maintained at 7-9 g/dl Hb maintained at 10 12 g/dl RESULTS: ALL OUTCOMES WERE EQUIVALENT OR BETTER IN THE RESTRICTIVE TRANSFUSION GROUP.

TRICC TRIAL OUTCOMES THAT WERE BETTER IN THE RESTRICTIVE TRANSFUSION GROUP OUTCOME RESTRICT TX LIBERAL TX P VALUE In hospital mortality 22.3 % 28.1 % 0.05 30 day mortality < 55 yr 5.7 % 13 % 0.02 APACHE score < 20 8.7 % 16.1 % 0.03 Myocardial infarction 0.07 % 2.9 % 0.02 CHF 5.3 % 10.7 % < 0.01

TRICC TRIAL OUTCOMES THAT WERE STATISTICALLY EQUIVALENT IN BOTH GROUPS OUTCOME RESTRICT TX LIBERAL TX P VALUE 30 day mortality 18.7 % 23.3 % 0.11 - cardiac patients 22.3% 22.9 % 0.69 Long-term mortality 22.7 % 26.5 % 0.23 Pneumonia 20.8 % 20.5 % 0.92 Other infections 10 % 11.9 % 0.38 Hospital LOS 34.8 days 35.5 days 0.58

There was no subset of patients that had a worse outcome with restrictive transfusion compared to liberal transfusion. ie: WITHOLDING blood did no harm. GIVING blood often did harm

EFFICACY OF RBC TRANSFUSION IN THE CRITICALLY ILL: A SYSTEMATIC REVIEW OF LITERATURE Marik PE and Corwin HL, Crit Care Med 2008;36:2667-2674 45 studies: association between RBC TX and: 1. Primary outcome: Mortality (18 studies) 2. Secondary outcome: Morbidity: - acquired infections (22 studies) - ARDS (6 studies) - Multiorgan dysfunction syndrome (3 studies) RESULTS: Risks of RBC TX > benefits: 42 of 45 studies Neutral (no difference in outcome): Benefit > risk: 2 of 45 studies in 1 subgroup of a single study (elderly patients with an acute MI and a Hct <30%,? euvolumic)

Multiple studies: similar results 2008: (Koch CG, et al. N Engl J Med 358:1229-39) Retrospective single center analysis of 6000 pts undergoing CABG or Valve surgery: Tx of older RBC units (> 14 days) = worse outcomes: Increased: - in-hospital mortality, (P= 0.004) - 1 yr mortality (P<0.001) - intubation >72 h (P<0.001) - sepsis (P=0.01) - renal failure (P=0.003) 2004: (Corwin HL, et al, Crit Care Med 32(1):39-52) Prospective multicenter observational cohort study, 4892 ICU pts: The # of RBC units transfused (but not the baseline Hb) is an independent predictor of worse outcome: - longer hospital stay - longer ICU stay - increased mortality

Multiple studies: similar results 2004: Shorr AF et al, Crit Care Med 32(3):666-674. Secondary analysis of a prospective multicenter observational cohort study, 4892 ICU pts without pneumonia at ICU admission who then required at least 48 h of mechanical ventilation: CONCLUSION: RBC transfusion increases the risk of developing VAP in ICU patients, with a positive dose response relationship. 2008: Rawn J. Curr Opin Anaesthesiol Oct;21(5):664-8 Review: The silent risks of blood transfusion. CONCLUSION: The benefits of blood transfusion have never been conclusively demonstrated, but evidence of transfusion-related harm continues to accumulate. Given the transfusion triggers that currently predominate in clinical practice it appears that clinical outcomes could significantly improve with more widespread adoption of restrictive transfusion strategies.

?? WHATS GOING ON?? Q: Why is there no benefit from RBC Tx? A: Because current RBC Tx practice is unscientific (based on myths): MYTH 1: MYTH 2: MYTH 3: Anemia = low O2 delivery to tissues RBC Tx increases O2 delivery to tissues The Hb level correlates well with tissue oxygenation

MYTH 1: Anemia = low tissue O2 Anemia (defined as decreased red cell mass) in practice measured as decreased Hb. Compensatory mechanisms in normovolemic anemia maintain O2 delivery to the tissues: 1. decreased blood viscosity -> decreased vascular resistance -> increased venous return -> increased cardiac output (heart rate and stroke volume) 2. increased tissue O2 extraction (maintains tissue O2 to Hb 4.5 g/dl in healthy resting adults, 5 g/dl [Hct 15] in anesthetized adults) 3. increased tissue 2,3 DPG levels -> increased dissociation of O2 from Hb -> increased tissue O2 delivery

MYTH 2: RBC Tx increases tissue oxygenation NO evidence to prove this assumption. Indirect evidence that RBC transfusion DECREASES tissue oxygenation (therefore usually WORSE outcomes)! WHY? due to 1. the RBC STORAGE DEFECT 2. Increased blood viscosity

RBC STORAGE DEFECT VARIABLE CHANGE TIME COURSE EFFECT OUTCOME RBC 2,3 DPG Decreased Near 0 after 2-3 days Increased affinity of Hb for O2 (more tightly bound) Decreased O2 delivery to tissues RBC Nitric Oxide (NO) Decreased Very rapid (4 fold decrease within 3 hrs) 1. RBC unable to dilate capillaries Sluggish microcirculation 2. RBC suck up vascular & tissue NO vasoconstriction Decreased O2 delivery to tissues RBC SHAPE Flexible biconcave disc rigid spiky ball (Echinocyte) 5 10 d: spicules 15 28 d: spherocyte RBC unable to deform and squeeze through capillaries Sluggish microcirculation Decreased O2 delivery to tissues

RBC STORAGE DEFECT VARIABLE CHANGE TIME COURSE EFFECT OUTCOME K+ RBC K+ decreases Rapid, progressive Hyperkalemia Cardiac and metabolic effects EC K+ increases LACTATE increases Progressive Pro-acidotic CELL FREE Hb increases Progressive Highly oxidative & cytotoxic, esp. to endothelial cells Proinflammatory and prothrombotic effects

RBC STORAGE DEFECT VARIABLE CHANGE TIME COURSE Inflammatory and prothrombotic Cytokines Platelet microparticles & WBC membrane fragments EFFECT Increased Progressive Increased: - ARDS, - SIRS, - Immunosupression OUTCOME Increased: - Infections - Organ failure - Cancer recurrence - Death Increased Progressive As above As above ATP Decreased Progressive Loss of membrane structure and integrity

MYTH 3: Hg level reflects tissue oxygenation In a euvolemic patient, Hb level reflects only the degree of anemia, NOT the tissue oxygenation. If dehydrated/hypovolemic: Hb level is artifactually high (ie: patient may be anemic, but Hb level appears normal) If overhydrated/hypervolemic: patient may have a normal red cell mass, but the Hb level appears low (in the anemic range) *****

Guideline: first do no harm! Acute blood loss: rapid loss of up to 1.5 to 2 liters (30 40 % of blood volume) -> rapid infusion of crystalloids (order Type & Screen)-> assess clinically: Vital signs stable: treat the cause of blood loss, no RBC Tx; continue to monitor Unstable or symptomatic (Hypotension, tachycardia, dyspnea etc): rule out causes other than anemia, and treat specifically (pressors, diuretics, oxygen etc). Unstable/symptomatic and no other likely cause: Tx 1 unit of prbc and re-evaluate clinically the need for each additional unit. Acute blood loss > 30 40 % of blood volume: - as above, but often require blood Tx.

GUIDELINE: first do no harm! CHRONIC ANEMIA: DO NOT TRANSFUSE. - Determine and treat the cause of the anemia (polypectomy, hysterectomy, iron, vit B 12, erythropoietin etc.) - If non-responsive to treatment: Is patient symptomatic? symptoms and/or signs of cardiovascular or cerebrovascular compromise (hypotension, tachycardia, dyspnea, dizziness, angina). If no: DO NOT TRANSFUSE Is patient euvolemic? (Give fluids first: see if symptoms resolve). Is another etiology more likely (than anemia) for the symptoms: If yes: DO NOT TRANSFUSE.

RBC Tx Guidelines Chronic anemia: determine cause and treat. Chronic anemia not responsive to specific treatment: No signs and symptoms: do not Tx. Continue to monitor. Hypotension, tachycardia, dyspnea, dizziness: ensure euvolemia and re-evaluate. If still symptomatic, and no other causes of S&S: Tx one unit and re-evaluate clinically the need for each additional unit.

THE TEAMWORK CHALLENGE: LOOK FOR EVIDENCE THAT: - RBC Tx increases tissue O2 delivery - RBC Tx improves patient outcomes in euvolemic patients. Email: rana.samuel@va.gov

?? WHY IS THIS A SUITABLE TOPIC FOR DISCUSSION AT ANNUAL RC MEET?? - Because our role can (and does) go beyond ensuring compliance with rules and regulations. - Because the VA nationally wants to transition to best evidence based practice - Because I want to tap into the phenomenal collective experience and expertise represented here

PROOF THAT EDUCATION AND UTILIZATION REVIEW ARE EFFECTIVE: 25% less prbc usage (04 08 avg: 800 units/yr, 09 avg: 600 units/yr) 40% decrease in Transfusion costs (1.1 million -> 660,000 $) BLOOD PRODUCTS TRANSFUSED FY 2007-2008 1000 900 800 700 600 500 400 RBC FFP PLT SINGLES PLT PHERESIS CRYO AUTO PRODUCTS DIRECTED PRODUCTS 300 200 100 0 1ST QTR/2007 2ND QTR 3RD QTR 4TH QTR 1ST QTR/2008 2ND QTR 3RD QTR 4TH QTR 1ST QTR/2009 2ND QTR 3RD QTR 4TH QTR RBC 759 774 802 688 899 904 810 799 562 559 FFP 167 119 99 95 170 201 205 175 147 73 PLT SINGLES 5 5 10 5 10 0 0 0 0 0 PLT PHERESIS 61 56 34 53 48 56 59 51 56 36 CRYO 10 0 0 10 10 10 10 10 0 0 AUTO PRODUCTS 0 0 0 0 0 0 0 0 0 0 DIRECTED PRODUCTS 0 0 0 0 0 0 0 0 0 0

THANK YOU! Q s?